RedHill Biopharma (RDHL) Short term Debt (2020 - 2022)
RedHill Biopharma's (RDHL) quarterly Short term Debt came in at $113.9 million in Q3 2022, up 36.33% year-over-year from $83.5 million in Q3 2021, and up 31.79% quarter-over-quarter from $86.4 million in Q1 2022.
Powered by 
Analysis
RedHill Biopharma (RDHL) Short term Debt (2020 - 2022) Analysis & Trends
RedHill Biopharma (RDHL) has reported Short term Debt for 3 consecutive years, with $113.9 million the latest figure, recorded in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 113.86 Mn |
| Mar 31, 2022 | 86.40 Mn |
| Sep 30, 2021 | 83.52 Mn |
| Mar 31, 2021 | 82.52 Mn |
| Sep 30, 2020 | 80.27 Mn |
| Mar 31, 2020 | 78.17 Mn |